

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Heart failure	BET bromodomain	<p>Cell culture and rodent studies suggest BET bromodomain inhibitors could help treat heart failure. In rodent and human heart tissue, the BET bromodomain-containing protein bromodomain containing 4 (BRD4) was strongly expressed. In neonatal rat ventricular cardiomyocytes, a series of BET bromodomain inhibitors decreased hypertrophy compared with vehicle control. In the transverse aortic constriction mouse model of cardiac hypertrophy, a BET bromodomain inhibitor improved cardiac function and decreased histological features of heart failure compared with vehicle. Next steps could include testing BET bromodomain inhibition in additional animal models.</p> <p>Tensha Therapeutics Inc., cofounded by James Bradner, has the BET bromodomain inhibitor TEN-010 in preclinical development for cancer. At least three other companies have BET bromodomain inhibitors in Phase I testing or preclinical development to treat cancer.</p> <p>SciBX 6(34); doi:10.1038/scibx.2013.928 Published online Sept. 5, 2013</p>	Patent and licensing status unavailable	<p>Anand, P. <i>et al. Cell</i>; published online Aug. 1, 2013; doi:10.1016/j.cell.2013.07.013</p> <p>Contact: Saptarsi M. Haldar, Case Western Reserve University School of Medicine, Cleveland, Ohio e-mail: saptarsi.haldar@case.edu</p> <p>Contact: James E. Bradner, Dana-Farber Cancer Institute, Boston, Mass. e-mail: james_bradner@dfci.harvard.edu</p>